152 related articles for article (PubMed ID: 32123492)
1. Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells.
Naba NM; Tolay N; Erman B; Sayi Yazgan A
Turk J Biol; 2020; 44(1):15-23. PubMed ID: 32123492
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin resistance in breast cancer xenografts and cell lines can be counterweighted by microRNA-140-3p, through PD-L1 suppression.
Zhang X; Wang C; Huang C; Yang J; Wang J
Histol Histopathol; 2023 Oct; 38(10):1193-1204. PubMed ID: 36621840
[TBL] [Abstract][Full Text] [Related]
3. Platycodin D from Platycodonis Radix enhances the anti-proliferative effects of doxorubicin on breast cancer MCF-7 and MDA-MB-231 cells.
Tang ZH; Li T; Gao HW; Sun W; Chen XP; Wang YT; Lu JJ
Chin Med; 2014; 9():16. PubMed ID: 24982689
[TBL] [Abstract][Full Text] [Related]
4. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer.
Chen YL; Wang GX; Lin BA; Huang JS
Cell Biol Int; 2020 May; 44(5):1224-1236. PubMed ID: 32068322
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
7. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells.
Zuo Y; Zheng W; Liu J; Tang Q; Wang SS; Yang XS
Neoplasma; 2020 Jan; 67(1):93-101. PubMed ID: 31777260
[TBL] [Abstract][Full Text] [Related]
8. miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint.
Li D; Wang X; Yang M; Kan Q; Duan Z
Exp Cell Res; 2019 Jul; 380(1):20-28. PubMed ID: 30904483
[TBL] [Abstract][Full Text] [Related]
9. MALAT-1: Immunomodulatory lncRNA hampering the innate and the adaptive immune arms in triple negative breast cancer.
Mekky RY; Ragab MF; Manie T; Attia AA; Youness RA
Transl Oncol; 2023 May; 31():101653. PubMed ID: 36907052
[TBL] [Abstract][Full Text] [Related]
10. Exosomal transfer of circ_0006174 contributes to the chemoresistance of doxorubicin in colorectal cancer by depending on the miR-1205/CCND2 axis.
Zhang Y; Tan X; Lu Y
J Physiol Biochem; 2022 Feb; 78(1):39-50. PubMed ID: 34792792
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
[TBL] [Abstract][Full Text] [Related]
12. Polymeric Hybrid Nanomicelles for Cancer Theranostics: An Efficient and Precise Anticancer Strategy for the Codelivery of Doxorubicin/miR-34a and Magnetic Resonance Imaging.
Xie X; Chen Y; Chen Z; Feng Y; Wang J; Li T; Li S; Qin X; Wu C; Zheng C; Zhu J; You F; Liu Y; Yang H
ACS Appl Mater Interfaces; 2019 Nov; 11(47):43865-43878. PubMed ID: 31684723
[TBL] [Abstract][Full Text] [Related]
13. Ursolic Acid Enhances Cytotoxicity of Doxorubicin-Resistant Triple-Negative Breast Cancer Cells via
Lu Q; Chen W; Ji Y; Liu Y; Xue X
Cancer Biother Radiopharm; 2022 Oct; 37(8):673-683. PubMed ID: 33493421
[No Abstract] [Full Text] [Related]
14. Knockdown of Long Non-Coding RNA XIST Inhibited Doxorubicin Resistance in Colorectal Cancer by Upregulation of miR-124 and Downregulation of SGK1.
Zhu J; Zhang R; Yang D; Li J; Yan X; Jin K; Li W; Liu X; Zhao J; Shang W; Yu T
Cell Physiol Biochem; 2018; 51(1):113-128. PubMed ID: 30439718
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.
Wang J; Shang S; Li J; Deng H; Ouyang L; Xie H; Zhu H; Li Y; Zuo C
Cancer Manag Res; 2020; 12():4999-5008. PubMed ID: 32612387
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways.
Chuangchot N; Jamjuntra P; Yangngam S; Luangwattananun P; Thongchot S; Junking M; Thuwajit P; Yenchitsomanus PT; Thuwajit C
Breast Cancer Res; 2023 Jul; 25(1):86. PubMed ID: 37480115
[TBL] [Abstract][Full Text] [Related]
17. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
[TBL] [Abstract][Full Text] [Related]
18. Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.
Liu H; Wang Y; Li X; Zhang YJ; Li J; Zheng YQ; Liu M; Song X; Li XR
Tumour Biol; 2013 Jun; 34(3):1713-22. PubMed ID: 23430586
[TBL] [Abstract][Full Text] [Related]
19. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
[TBL] [Abstract][Full Text] [Related]
20. Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy.
Tan Q; Wang H; Hu Y; Hu M; Li X; Aodengqimuge ; Ma Y; Wei C; Song L
Cancer Sci; 2015 Aug; 106(8):1023-32. PubMed ID: 26041409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]